Posted by Michael Wonder on 15 Sep 2025
ICER to undertake special report on Crohn’s disease and ulcerative colitis for CMS as part of public comment process on Medicare drug price negotiations
15 September 2025 - Report to reflect legislative specifications in the Inflation Reduction Act and most recent CMS guidance regarding price negotiations.
The ICER announced today that it will develop a special report for the Centers for Medicare & Medicaid Services (CMS) for treating Crohn’s disease and ulcerative colitis. ICER will evaluate Entyvio (vedolizumab, Takeda). This report will be submitted to CMS as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.
